wo years on from the start of Russia’s full-scale invasion, the Ukrainian business community is actively reshaping the country’s narrative to attract investments and promote deal-making, moving away from its war-torn image and global economic uncertainties.
Significant civilian casualties and extensive damage to infrastructure and productive assets in 2022 meant traditional players in sectors like metallurgy, agriculture and retail faced reduced investment potential, prompting a shift toward the IT sector.
However, the Ukrainian economy has shown signs of recovery. GDP grew by approximately 5% last year and there has been a gradual return of investment interest. The National Bank of Ukraine’s monetary policy of maintaining a stable exchange rate has also helped stabilize prices and inflation, fostering increased consumer confidence and higher retail turnovers.
This rebound underscores the Ukrainian economy’s resilience, supported by crucial military and monetary assistance provided by international allies. Several industries have emerged as potential powerhouses for Ukrainian reconstruction:
Furthermore, the Ukraine Development Fund (established with backing from leading U.S. investment firms BlackRock and JPMorgan) shows that Ukraine is already thinking ahead and is ready to rebuild. These endeavors underscore Ukraine’s commitment to overcoming challenges, increasing manufacturing, securing exports and fostering new investment opportunities, setting the stage for improved investor confidence as the country looks forward to 2024.
The economic outlook for Ukraine is still shaky, but history teaches that countries under pressure with a highly motivated and educated population can achieve amazing economic results.
Before the Russian invasion two years ago, Ukraine was an important provider of high-throughput screening (HTS) compounds and played an important role in clinical trials.
As documented by the NIH and other sources, Ukrainian fine chemical companies such as Enamine Ltd and Uorsy or the fine chemical platform Chemspace are important actors in HTS compounds, which are essential for drug discovery. These compounds are critical to the pharmaceutical industry as they enable the rapid screening of thousands to millions of chemical compounds for biological activity, playing a key role in the efficient identification and validation of new drug targets. In the early days of the conflict the disruption of production and logistics provided challenges for drug discovery and development.
The conflict in Ukraine has also disrupted the country’s important role in cancer clinical trials. Before the war, Ukraine participated in a large number of randomized clinical trials in oncology. Since the war started no new trials have been started in Ukraine. Existing trials, however, were not disrupted.
According to a recent study from the Swiss Federal Institute of Technology in Lausanne, 18% of Ukraine’s scientists have fled due to the war and research capacity is down 20% . This is particularly difficult since Ukrainian life sciences companies and hospitals occupy relevant links in the entire drug discovery and development process.
However, as noted elsewhere in this article, the Ukrainian economy has shown signs of recovery. Several industries have emerged as potential powerhouses for Ukrainian reconstruction, in particular IT and life sciences. In the life sciences sector, Ukrainian enterprises, researchers and hospitals have proven to be resilient and looking for solutions to cope with difficult situation. Clinical research organizations (CROs) which have been active in the Ukraine are making efforts to resume clinical trials in Ukraine, particularly in relatively safe cities such as Lviv. In the HTS arena, international collaboration is picking up: Late last year U.S. group Recursion and Enamine announced a partnership to generate enriched screening libraries for the global drug discovery industry.